Meghmani Finechem Ltd

Epigral Limited has announced the closure of its trading window for all insiders, directors, promoters, designated persons, and their immediate relatives. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code. The trading window will remain shut from October 1, 2026, until 48 hours after the declaration of the Un-Audited Financial Results for the Second Quarter and Half Year ended September 30, 2026. The company is utilizing Central Depository Service Limited to freeze PAN at the security level for its ISIN to restrict trading by designated persons and their relatives, adhering to recent SEBI circulars. The date for the Board Meeting to approve these financial results will be announced later.

Epigral Limited announced its un-audited financial results for Q1 FY27, reporting a 25% year-on-year increase in Profit After Tax (PAT) to ₹99 crore, up from ₹79 crore in Q1 FY26. Quarterly revenue grew by 15% to ₹709 crore from ₹615 crore in the prior year period. The company's board also approved a significant capital expenditure of approximately ₹600 crore for entering the Epoxy Resin and Formulations business, including setting up a Multi-Purpose Plant (MPP). This strategic expansion aims to leverage internal raw material sourcing, particularly Epichlorohydrin (ECH) and Caustic Soda, for advanced materials and specialty chemicals. The commercial plant is expected to be commissioned in H2FY28, with a pilot plant operational by Q2FY27.

Epigral Ltd announced plans to establish a new manufacturing facility for Epoxy Resin & Formulations and a Multi-Purpose Plant at its existing Dahej, Gujarat site. The expansion initiative is a strategic move to broaden its product portfolio and cater to increasing market demand. The project requires an estimated investment of ₹600 crore, to be financed through a mix of debt and internal accruals. The proposed capacity for Epoxy Resin & Formulations is 1,25,000 TPA, with both plants expected to be operational by H2 FY2028.

Epigral Limited announced the outcome of its Board Meeting held on July 27, 2026. The board approved and took on record the Un-Audited Financial Results (Standalone & Consolidated) for the First Quarter ended June 30, 2026. The company also noted the Limited Review Report from its statutory auditors, M/s. S R B C & CO LLP. The meeting took place at the company's registered office in Ahmedabad.

Epigral Limited announced its unaudited financial results for the first quarter ended June 30, 2026. The Board of Directors approved the standalone and consolidated results, along with the limited review report from statutory auditors M/s. S R B C & CO LLP. The meeting was held on July 27, 2026, at the company's registered office in Ahmedabad. The results were prepared in accordance with Ind AS.

Epigral Limited has responded to a clarification sought by BSE Limited regarding an increase in the company's trading volume. The company stated that it has made all necessary disclosures as per SEBI regulations, including all price-sensitive information and events impacting operations or performance. Epigral Limited affirmed that no material information has been withheld. The company attributes the recent movement in volume and share price to general market conditions and market-driven factors, asserting no direct connection from the company's side to these movements. They will continue to comply with disclosure requirements within stipulated timelines.

Epigral Ltd has announced that its Board of Directors will convene on July 27, 2026. The primary agenda item for this meeting is to consider and approve the un-audited financial results for the first quarter ended June 30, 2026. Both standalone and consolidated results will be reviewed, along with the statutory auditors' limited review report. The meeting will also address any other business as permitted by the Chair. This announcement serves to inform the company's shareholders and members.

Epigral Limited has announced the incorporation of its wholly-owned subsidiary, Epigral Advanced Materials Limited, on July 7, 2026. The new entity, registered in India, will focus on the manufacturing of chemicals. The subsidiary has been established with a paid-up capital of ₹1,00,000, comprising 10,000 equity shares of ₹10 each. Epigral Limited will hold 100% shareholding in this new venture, which is considered a related party.

Epigral Limited has announced the closure of its trading window for all insiders, directors, promoters, designated persons, and their immediate relatives. This closure will be effective from Wednesday, July 1, 2026, and will remain in effect for 48 hours after the declaration of the Un-Audited Financial Results for the First Quarter ended June 30, 2026. The company is utilizing Central Depository Service Limited to restrict trading by freezing PAN at the security level for its ISIN, in compliance with SEBI regulations. The date for the Board Meeting to approve these financial results will be announced later.

Epigral Ltd has announced that its 19th Annual General Meeting (AGM) will be held on June 8, 2026, via video conferencing. The company has fixed June 1, 2026, as the cut-off date for e-voting eligibility and also as the record date to determine shareholders' entitlement for dividend for FY 2025-26, if approved. Remote e-voting will be available from June 4 to June 7, 2026. The Annual Report for FY 2025-26 and the AGM notice are available on the company's website.